Nkarta
CAR-NK company that shelved its oncology programmes after falling response rates and pivoted to autoimmune disease.
NKX101 (AML) response rate fell from 67% to 25% and was deprioritised; the CD19 CAR-NK NKX019 was withdrawn from lymphoma development and is now in phase 1 for lupus nephritis and other autoimmune conditions. A data point on the limits of unmodified CAR-NK persistence.
Pages like this
not linked directly; found by shared links- CompanySana Biotechnology
Shares CD19, Diffuse large B-cell lymphoma and the tag pivot.
- CompanyFate Therapeutics
Shares Off-the-shelf natural killer cells to sweep up residual disease, CAR-NK & CAR-macrophage, CD19, Diffuse large B-cell lymphoma.
- ProductEprenetapopt
Shares Acute myeloid leukaemia and the tag failure.
- InstitutionChinese PLA General Hospital
Shares CD19, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
- PersonChristopher R. Flowers
Shares CD19, Diffuse large B-cell lymphoma.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares CD19, Diffuse large B-cell lymphoma.
- CompanyMorphoSys (Novartis)
Shares CD19, Diffuse large B-cell lymphoma.
- ProductMagrolimab
Shares Acute myeloid leukaemia and the tag failure.